Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:40 AM
Ignite Modification Date:
2025-12-25 @ 2:40 AM
NCT ID:
NCT00675233
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Biopsy-confirmed diagnosis of 1 of the following:
* Mild to severe dysplasia of the larynx
* Dysplastic lesions \> 3 mm in thickness
* Squamous cell carcinoma in situ of the larynx
* T1 squamous cell carcinoma of the larynx
* Tumor \> 3 mm in thickness
* No T2-T4 squamous cell carcinoma of the larynx
* Newly diagnosed or recurrent disease
PATIENT CHARACTERISTICS:
* ECOG performance status 0-2
* Total bilirubin \> 2.0 mg/dL
* Creatinine \> 2.0 mg/dL
* SGOT \> 3 times upper limit of normal (ULN)
* Alkaline phosphatase \> 3 times ULN
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 3-6 months after completion of study treatment
* No porphyria
* No hypersensitivity to porphyrin or porphyrin-like compounds
PRIOR CONCURRENT THERAPY:
* Any prior therapy allowed
* At least 4 weeks since prior and no concurrent chemotherapy or radiotherapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00675233
Study Brief:
Protocol Section:
NCT00675233